MP
GALT icon

Mangrove Partners’s Galectin Therapeutics GALT Stock Holding History

Mangrove Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,783
Closed -$78.1K – 501
2025
Q4 		$78.1K Buy
+18,783
New +$98.9K 0.01% 358
2014
Q2 		– Sell
-200,000
Closed -$3.06M – 39
2014
Q1 		$3.06M Buy
+200,000
New +$2.85M 1.02% 28

Other funds holding GALT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Mangrove Partners's GALT Position: Q1 2026 in Review

Mangrove Partners sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 18,783 shares — an estimated $78.1K sold.

Mangrove Partners first reported a position in GALT in Q1 2014 and held it in 2 quarters. The position peaked at $3.06M in Q1 2014. 98 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Mangrove Partners reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Mangrove Partners sold 18,783 Galectin Therapeutics shares in Q1 2026, an estimated $78.1K.
  • Mangrove Partners first reported a position in Galectin Therapeutics in Q1 2014 and held it in 2 quarters.
  • Mangrove Partners's Galectin Therapeutics position peaked at $3.06M in Q1 2014.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.